<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Breast Cancer Res</journal-id><journal-title>Breast Cancer Research : BCR</journal-title><issn pub-type="ppub">1465-5411</issn><issn pub-type="epub">1465-542X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11056688</article-id><article-id pub-id-type="pmc">PMC13918</article-id><article-id pub-id-type="publisher-id">bcr-2-4-307</article-id><article-categories><subj-group subj-group-type="heading"><subject>Primary Research</subject></subj-group></article-categories><title-group><article-title><italic>BRCA1</italic> and <italic>BRCA2</italic> mutations in central and southern
		  Italian patients</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Ottini</surname><given-names>Laura</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref></contrib><contrib id="A2" contrib-type="author"><name><surname>D'Amico</surname><given-names>Cristina</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref></contrib><contrib id="A3" contrib-type="author"><name><surname>Noviello</surname><given-names>Cristiana</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib id="A4" contrib-type="author"><name><surname>Lauro</surname><given-names>Salvatore</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib id="A5" contrib-type="author"><name><surname>Lalle</surname><given-names>Maurizio</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib id="A6" contrib-type="author"><name><surname>Fornarini</surname><given-names>Giuseppe</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib id="A7" contrib-type="author"><name><surname>Colantuoni</surname><given-names>Orsola Anna</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib id="A8" contrib-type="author"><name><surname>Pizzi</surname><given-names>Claudia</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib id="A9" contrib-type="author"><name><surname>Cortesi</surname><given-names>Enrico</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib id="A10" contrib-type="author"><name><surname>Carlini</surname><given-names>Sandro</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib id="A11" contrib-type="author"><name><surname>Guadagni</surname><given-names>Fiorella</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib id="A12" contrib-type="author"><name><surname>Bianco</surname><given-names>Angelo Raffaele</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib id="A13" contrib-type="author"><name><surname>Frati</surname><given-names>Luigi</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib id="A14" contrib-type="author"><name><surname>Contegiacomo</surname><given-names>Alma</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib id="A15" contrib-type="author"><name><surname>Mariani-Costantini</surname><given-names>Renato</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib></contrib-group><aff id="I1"><label>1</label>University 'Gabriele D'Annunzio', Chieti, Italy.</aff><aff id="I2"><label>2</label>University 'La Sapienza', Rome, Italy.</aff><aff id="I3"><label>3</label>University 'Federico II', Naples, Italy.</aff><aff id="I4"><label>4</label>Regina Elena Cancer Institute, Rome, Italy.</aff><pub-date pub-type="ppub"><year>2000</year></pub-date><pub-date pub-type="epub"><day>31</day><month>3</month><year>2000</year></pub-date><volume>2</volume><issue>4</issue><fpage>307</fpage><lpage>310</lpage><ext-link ext-link-type="uri" xlink:href="http://breast-cancer-research.com/content/2/4/307"/><history><date date-type="received"><day>3</day><month>8</month><year>1999</year></date><date date-type="rev-request"><day>7</day><month>9</month><year>1999</year></date><date date-type="rev-recd"><day>28</day><month>2</month><year>2000</year></date><date date-type="accepted"><day>3</day><month>3</month><year>2000</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2000 Current Science Ltd</copyright-statement><copyright-year>2000</copyright-year><copyright-holder>Current Science Ltd</copyright-holder></permissions><abstract abstract-type="short"><p>Protein truncation test (PTT) and single-strand conformation
			 polymorphism (SSCP) assay were used to scan the <italic>BRCA1</italic> and
			 <italic>BRCA2</italic> genes in 136 unrelated Italian breast/ovarian cancer patients.
			 In the sample tested, <italic>BRCA1</italic> and <italic>BRCA2</italic> equally contributed to
			 site-specific breast cancer patients who reported one to two breast
			 cancer-affected first-/ second-degree relative(s) or who were diagnosed before
			 age 40 years in the absence of a family history of breast/ovarian cancer.
			 <italic>BRCA1</italic> and <italic>BRCA2</italic> mutations were mostly found in patients with
			 disease diagnosis before and after age 50 years, respectively. Moreover, in
			 cases with familial clustering of site-specific breast cancer, <italic>BRCA1</italic>
			 mostly accounted for tumours diagnosed before age 40 years and <italic>BRCA2</italic>
			 for tumours diagnosed after age 50 years. The <italic>BRCA1</italic> and <italic>BRCA2</italic>
			 mutation spectrum was consistent with a lack of significant founder effects in
			 the sample of patients studied.</p></abstract><abstract><sec><title>Introduction:</title><p>Germline <italic>BRCA1</italic> and <italic>BRCA2</italic> mutations account for
				most hereditary breast/ovarian cancers and are associated with male breast
				cancer. Furthermore, constitutional mutations in these genes may occur in
				breast/ovarian cancer patients that do not meet stringent criteria of
				autosomal-dominant predisposition. The relevance of <italic>BRCA1</italic> and
				<italic>BRCA2</italic> mutations in such patients is still debated.</p></sec><sec><title>Objectives:</title><p>We sought to determine the impact of <italic>BRCA1</italic> and
				<italic>BRCA2</italic> mutations in a population of patients from central and southern
				Italy. We analyzed the <italic>BRCA1</italic> and <italic>BRCA2</italic> coding regions in 136
				unrelated probands: 117 females with breast/ovarian cancer and 19 males with
				breast cancer. This population of patients was mostly representative of cases
				who are at risk for hereditary susceptibility, but who do not meet stringent
				criteria of autosomal-dominant predisposition.</p></sec><sec><title>Methods:</title><p>Probands, subclassified as follows, were consecutively recruited
				depending on informed consent from patients attending breast cancer clinics in
				Rome and Naples. Selection criteria for females were as follows: breast cancer
				with breast cancer family history [one to two first-/second-degree relative(s),
				<italic>n</italic> = 55]; breast cancer diagnosed before age 40 years (no
				breast/ovarian cancer family history, <italic>n</italic> = 28); bilateral breast cancer
				(regardless of age and family history, <italic>n</italic> =10); breast cancer
				associated with gastrointestinal, pancreatic or uterine cancers
				[synchronous/metachronous or in first-degree relative(s), <italic>n</italic> = 9];
				breast or ovarian cancer with family history of breast-ovarian/ovarian cancer
				(at least 1 first-/ second-degree relative, <italic>n</italic> = 10); and ovarian
				cancer with no breast/ovarian cancer family history (<italic>n</italic> = 5). Males
				with breast cancer were recruited regardless of age and family history.
				<italic>BRCA1</italic> exon 11 and <italic>BRCA2</italic> exons 10 and 11 were screened by PTT.
				Coding <italic>BRCA1</italic> exons 2, 3, 5-10 and 12-24 and <italic>BRCA2</italic> exons 2-9
				and 12-27 were screened by SSCP. Primers are listed in Table <xref ref-type="table" rid="T1">1</xref>. In 27 cases, analyzed by PTT along the entire <italic>BRCA1</italic>
				coding sequence, <italic>BRCA1</italic> SSCP analysis was limited to exons 2, 5, 20 and
				24. Mutations were verified by sequence analysis on two independent blood
				samples.</p></sec><sec><title>Results:</title><p>Deleterious germline <italic>BRCA1</italic>/<italic>BRCA2</italic> mutations were
				detected in 11 out of 136 cases (8%). Only three <italic>BRCA2</italic> mutations were
				novel. One <italic>BRCA2</italic> mutation recurred in two unrelated probands. Table
				<xref ref-type="table" rid="T2">2</xref> shows the mutations and data concerning carriers and
				their families. Table <xref ref-type="table" rid="T3">3</xref> shows correlations between
				<italic>BRCA1</italic>/<italic>BRCA2</italic> mutations and sex, age at disease diagnosis and
				familial clustering of breast/ovarian cancer in the total patient population.
				Table <xref ref-type="table" rid="T4">4</xref> shows the proportions of <italic>BRCA1</italic> and
				<italic>BRCA2</italic> mutations in females with site-specific breast and
				breast-ovarian/ovarian cancer. Table <xref ref-type="table" rid="T5">5</xref> shows the
				frequency of <italic>BRCA1</italic>/<italic>BRCA2</italic> mutations in males. <italic>BRCA1</italic>
				and <italic>BRCA2</italic> mutations, respectively, accounted for four out of 68 (6%)
				and one out of 68 (1%) cases diagnosed before age 50 years, and for one out of
				68 (1%) and five out of 68 (7%) cases diagnosed after age 50 years.
				<italic>BRCA1</italic> mutations were found in five out of 117 females (4%) and in none
				of 19 males (0%), and <italic>BRCA2</italic> mutations were found in four out of 117
				females (3%) and in two out of 19 males (10%). The proportions of
				<italic>BRCA1</italic> and <italic>BRCA2</italic> mutations coincided in site-specific female
				breast cancers (four out of 102; ie 4% each). <italic>BRCA1</italic> and <italic>BRCA2</italic>
				equally contributed to female breast cancers, with no familial clustering in
				those diagnosed before age 40 years (one out of 28; 4% each), and to female
				breast cancers, all ages, with familial clustering in one to two relatives
				(three out of 55; ie 5% each). In the latter subset of cases, <italic>BRCA1</italic>
				mostly accounted for tumours diagnosed before age 40 years (two out of eight;
				25%), and <italic>BRCA2</italic> for tumours diagnosed after age 50 years (three out of
				34; 9%). Regardless of family history, the respective contributions of
				<italic>BRCA1</italic> and <italic>BRCA2</italic> to site-specific female breast cancers
				diagnosed before age 40 years were 8% (three out of 36) and 3% (one out of 36).
				One <italic>BRCA1</italic> mutation was detected among the 15 female probands from
				breast-ovarian/ovarian cancer families (7%). Among male breast cancers,
				<italic>BRCA2</italic> mutations were identified in one out of five (20%) cases with
				family history and in one out of 14 (7%) apparently sporadic cases. No
				<italic>BRCA1</italic> or <italic>BRCA2</italic> mutations were found in female probands with
				nonfamilial bilateral breast cancer (10 cases) or in those with breast cancer
				associated with gastrointestinal, pancreatic or uterine cancers,
				synchronous/metachronous or in first-degree relative(s) (nine cases). These
				cases were all diagnosed after age 40 years.</p></sec><sec><title>Discussion:</title><p>Our results indicate a lack of relevant founder effects for
				<italic>BRCA1-</italic> and <italic>BRCA2</italic>-related disease in the sample of patients
				studied, which is consistent with other Italian studies and with ethnical and
				historical data. Overall, the contribution of <italic>BRCA1</italic> and <italic>BRCA2</italic>
				to breast/ovarian cancer in Italian patients appears to be less significant
				than in patients from communities with founder mutations. The present study is
				in agreement with direct estimates on other outbred populations, indicating
				that 7-10% of all female breast cancers that occur in patients aged under 40
				years are due to <italic>BRCA1</italic>/<italic>BRCA2</italic>.</p><p>We found that <italic>BRCA1</italic> and <italic>BRCA2</italic> equally
				contributed to site-specific breast cancers who had one/two breast
				cancer-affected first-/second-degree relative(s) or who were diagnosed within
				age 40 years in the absence of family history. This is consistent with recent
				data that indicated that the respective frequencies of <italic>BRCA1</italic> and
				<italic>BRCA2</italic> mutations are comparable in early onset breast cancer.
				Considering the total population of patients analyzed here, however,
				<italic>BRCA1</italic> and <italic>BRCA2</italic> mutations were mostly found in cases with
				disease diagnosis before and after age 50 years, respectively. Moreover, in
				cases with familial clustering of site-specific breast cancer, <italic>BRCA1</italic>
				mostly accounted for tumours diagnosed before age 40 years, and <italic>BRCA2</italic>
				for tumours diagnosed after age 50 years. This is in agreement with a trend,
				which has been observed in other populations, for the proportion of cases with
				<italic>BRCA2</italic> mutations to increase, and the proportion with mutations in
				<italic>BRCA1</italic> to decrease, as the age at cancer onset increases.</p><p>As in other studies, the frequency of
				<italic>BRCA1</italic>/<italic>BRCA2</italic> mutations taken together was lower than the
				estimated frequencies at comparable ages for all susceptibility alleles derived
				from the Contraceptive and Steroid Hormones (CASH) study. The discrepancy
				between direct data deriving from <italic>BRCA1</italic>/<italic>BRCA2</italic> mutational
				analysis and CASH estimates could be due to several factors, including
				contribution of gene(s) other than <italic>BRCA1</italic>/<italic>BRCA2</italic>, differences
				between populations and relative insensitivity of mutational screening. Only
				<italic>BRCA1</italic> mutations were found in breast/ovarian and site-specific ovarian
				cancer families. <italic>BRCA2</italic>, but not <italic>BRCA1</italic> mutations were found in
				the male breast cancers. The overall proportion of males with <italic>BRCA2</italic>
				mutations was high when compared with data from other studies on outbred
				populations, but was low compared with data from populations with founder
				effects.</p><p>The present results should be regarded as an approximation,
				because the following types of mutation are predicted to escape detection by
				the screening strategy used: mutations in noncoding regions; missense mutations
				within <italic>BRCA1</italic> exon 11 and <italic>BRCA2</italic> exons 10 and 11; large gene
				deletions; and mutations within the first and last 180 nucleotides of the
				amplicons analyzed by PTT.</p></sec></abstract><kwd-group><kwd>BRCA1</kwd><kwd>BRCA2</kwd><kwd>breast</kwd><kwd>carcinoma</kwd><kwd>germline mutations</kwd><kwd>Italy</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>The proportion of breast cancers that are attributable to
		  autosomal-dominant susceptibility genes is estimated to be approximately 7% in
		  the general population [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>]. Germline mutations of the
		  <italic>BRCA1</italic> and <italic>BRCA2</italic> genes are estimated to contribute to the
		  majority of the breast cancers that have very early disease onset, strong
		  family history and/or association with ovarian cancer [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>].
		  <italic>BRCA1</italic> and <italic>BRCA2</italic> also account for a proportion of common
		  breast/ovarian cancer patients that typically do not meet stringent criteria
		  for highly penetrant autosomal-dominant cancer predisposition, but rather
		  report one or two disease-affected relatives and/or manifest an early disease
		  onset [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>]. Knowledge of the contribution of <italic>BRCA1</italic> and
		  <italic>BRCA2</italic> to breast cancer in these patients is still incomplete [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B8">8</xref>]. A better understanding of the
		  frequencies of <italic>BRCA1</italic> and <italic>BRCA2</italic> mutations in such moderate
		  risk patients is fundamental to our appreciation of the importance of these
		  genes as a cause of disease in the general population. Furthermore,
		  <italic>BRCA2</italic> and, to a lesser extent, <italic>BRCA1</italic> also appear to be
		  responsible for an important, but still debated proportion of male breast
		  cancers [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B14">14</xref>].</p><p>We analyzed the entire <italic>BRCA1</italic> and <italic>BRCA2</italic> coding
		  regions in 136 unrelated probands: 117 female breast/ ovarian cancer patients
		  and 19 male breast cancer patients. This sample, selected from patients
		  attending breast cancer clinics in Rome and Naples, was primarily drawn from
		  moderate-risk families originating from central and southern Italy, a
		  geographic region that is known to be ethnically heterogeneous [<xref ref-type="bibr" rid="B15">15</xref>]. We used a screening strategy based on a combination of
		  PTT and SSCP analyses, techniques that are mutually complementary in
		  sensitivity and that may identify more than 80% of mutations [<xref ref-type="bibr" rid="B16">16</xref>].</p></sec><sec sec-type="methods"><title>Patients and methods</title><sec><title>Patients</title><p>A total of 136 probands, subclassified as listed below according to
			 selection criteria, were consecutively recruited depending on informed consent
			 from among breast/ovarian cancer patients attending the breast cancer clinics
			 participating in the study in Rome and Naples. The patients originated from the
			 regions of Latium and Abruzzo (central Italy) and Campania and Molise (southern
			 Italy). They included 55 patients with female breast cancer, any age, with
			 breast cancer in one or two first-/second-degree relative(s); 28 patients with
			 female breast cancer diagnosed before age 40 years, who reported no family
			 history of breast/ovarian cancer; 10 patients with female breast/ovarian
			 cancer, any age, with a family history of ovarian/breast-ovarian cancer in at
			 least one first-/second-degree relative; 19 patients with male breast cancer,
			 selected regardless of age and family history; five patients with ovarian
			 cancer, any age, who reported no familial history of breast/ovarian cancer; 10
			 patients with bilateral breast cancer, selected regardless of age, who reported
			 no family history of breast/ovarian cancer; and nine patients with breast
			 cancer associated with gastrointestinal, pancreatic or uterine cancers,
			 synchronous/metachronous, or in first-degree relative(s), selected regardless
			 of age. Analysis of genomic DNA, RNA and cDNA preparations from peripheral
			 blood lymphocytes were performed following standard procedures. The research
			 protocol was approved by the ethical committee of the University
			 'Gabriele D'Annunzio'.</p></sec><sec><title>BRCA1 and BRCA2 mutational analysis</title><p>All patients were analyzed for constitutional mutations throughout
			 the entire <italic>BRCA1</italic> and <italic>BRCA2</italic> coding regions. <italic>BRCA1</italic>
			 exon 11 and <italic>BRCA2</italic> exons 10 and 11 were screened by PTT from genomic
			 DNA using the primers listed in Table <xref ref-type="table" rid="T1">1</xref>. Coding
			 <italic>BRCA1</italic> exons 2, 3, 5-10 and 12-24, and <italic>BRCA2</italic> exons 2-9 and
			 12-27 were screened by SSCP analysis using previously reported primers [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B17">17</xref>]. Primers for <italic>BRCA2</italic>
			 exons 14 and 18 and for a 281 bp <italic>BRCA2</italic> fragment that encompassed the
			 intron 10/exon 11 boundary are reported in Table <xref ref-type="table" rid="T1">1</xref>. In 27
			 cases, who were analyzed by PTT along the entire <italic>BRCA1</italic> coding sequence
			 as described by Friedman <italic>et al</italic> [<xref ref-type="bibr" rid="B17">17</xref>],
			 <italic>BRCA1</italic> SSCP analysis was limited to exons 2, 5, 20 and 24, to identify
			 missense mutations that are reportedly frequent in these exons and to allow a
			 better investigation of the 5' and 3' ends of the coding sequence.
			 PTT and polymerase chain reaction (PCR)-SSCP were performed as described
			 previously [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B18">18</xref>]. When truncated peptides or variant SSCP conformers were
			 identified, genomic DNA was reamplified and directly sequenced with the PCR
			 product sequencing kit (Sequenase Version 2.0, USB-Amersham, Cleveland, OH,
			 USA). Mutations were verified on two independent blood samples.</p></sec></sec><sec><title>Results</title><p>Deleterious germline <italic>BRCA1</italic>/<italic>BRCA2</italic> mutations were
		  detected in 11 out of 136 cases (8%). Table <xref ref-type="table" rid="T2">2</xref> shows the
		  mutations and data concerning carriers and their families. Table <xref ref-type="table" rid="T3">3</xref> shows correlations between <italic>BRCA1</italic>/<italic>BRCA2</italic>
		  mutations and sex, age at disease diagnosis and familial clustering of
		  breast/ovarian cancer in the total patient population. Table <xref ref-type="table" rid="T4">4</xref> shows the proportions of <italic>BRCA1</italic> and <italic>BRCA2</italic>
		  mutations in females with site-specific breast and breast-ovarian/ovarian
		  cancer. Table <xref ref-type="table" rid="T5">5</xref> shows the frequency of
		  <italic>BRCA1</italic>/<italic>BRCA2</italic> mutations in males.</p><p>The five deleterious <italic>BRCA1</italic> mutations (Table <xref ref-type="table" rid="T2">2</xref>) included four frameshift mutations (<italic>BRCA1</italic>
		  1479delAG, <italic>BRCA1</italic> 1623del5bp, <italic>BRCA1</italic> 3880delAG, <italic>BRCA1</italic>
		  5083del19bp) and one missense mutation (<italic>BRCA1</italic> 300TtoG). These
		  mutations were already reported in the literature [<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B22">22</xref>] or in the Breast Cancer
		  Information Core electronic database
		  (<ext-link ext-link-type="uri" xlink:href="http://nchgr.nih.gov/Intramural_research/Lab_transfer/Bic/"/>).
		  In addition to the above described deleterious mutations, the neutral
		  <italic>BRCA1</italic> coding variants Glu1038Gly and, in homozygosity, Ser1613Gly were
		  found in two patients [<xref ref-type="bibr" rid="B20">20</xref>]. A novel C to G transversion,
		  affecting the conserved C/T residues of the consensus sequence for the 3'
		  -splice site of <italic>BRCA1</italic> intron 22, was also found in a 60-year-old woman
		  with synchronous breast and gastric cancers, but no family history of cancer.
		  Sequence analysis from cDNA and genomic DNA revealed normal exon 23 and exon 24
		  transcripts. Allele expression analysis was not feasible, because the patient
		  was homozygous at multiple <italic>BRCA1</italic> polymorphisms.</p><p>Five deleterious <italic>BRCA2</italic> mutations, all localized in exon 11
		  and including three nonsense and two frameshift mutations, were identified in
		  six patients (Table <xref ref-type="table" rid="T2">2</xref>). <italic>BRCA2</italic> 4109TtoA,
		  <italic>BRCA2</italic> 4339CtoT and <italic>BRCA2</italic> 5117CtoG are novel, whereas
		  <italic>BRCA2</italic> 5950delTC and <italic>BRCA2</italic> 6696delTC were previously reported
		  [<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B24">24</xref>]. One mutation
		  (<italic>BRCA2</italic> 6696delTC) recurred in two unrelated probands. The haplotype of
		  the mutation-bearing chromosomes could not be reconstructed, because DNA
		  samples from relatives of the two patients were not available.</p><p><italic>BRCA1</italic> and <italic>BRCA2</italic>, respectively, accounted for four
		  out of 68 (6%) and one out of 68 (1%) patients diagnosed before age 50 years,
		  and for one out of 68 (1%) and five out of 68 (7%) cases diagnosed after age 50
		  years. <italic>BRCA1</italic> mutations were found in five out of 117 females (4%) and
		  in none of 19 males (0%), and <italic>BRCA2</italic> mutations were found in four out
		  of 117 females (3%) and in two out of 19 males (10%). <italic>BRCA1</italic> and
		  <italic>BRCA2</italic> mutations accounted for the same number of cases among patients
		  with family history of breast/ovarian cancer (four out of 66; ie 4% each),
		  whereas <italic>BRCA1</italic> and <italic>BRCA2</italic> mutations, respectively, accounted
		  for one out of 66 (1%) and for two out of 64 (3%) of the cases without a family
		  history (Table <xref ref-type="table" rid="T3">3</xref>).</p><p>In site-specific female breast cancers, the proportions of
		  <italic>BRCA1</italic> and <italic>BRCA2</italic> mutations coincided (four out of 102, ie 4%
		  each). <italic>BRCA1</italic> and <italic>BRCA2</italic> equally contributed to female breast
		  cancers with no familial clustering diagnosed before age 40 years (one out 28;
		  4% each) and to female breast cancers, all ages, with familial clustering in
		  one or two relatives (three out of 55; 5% each). In the latter subset of cases,
		  <italic>BRCA1</italic> mostly accounted for tumours diagnosed before age 40 years (two
		  out of eight; 25%) and <italic>BRCA2</italic> for tumours diagnosed after age 50 years
		  (three out of 34; 9%). Regardless of family history, the respective
		  contributions of <italic>BRCA1</italic> and <italic>BRCA2</italic> to site-specific female
		  breast cancers diagnosed before age 40 years were 8% (three out of 36) and 3%
		  (one out of 36). One <italic>BRCA1</italic> mutation was detected among the 15 female
		  probands from breast-ovarian/ovarian cancer families (7%). This patient was
		  among the 10 who had a family history of breast/ovarian cancer (one out of 10,
		  10%; Table <xref ref-type="table" rid="T4">4</xref>).</p><p>Among male breast cancers, <italic>BRCA2</italic> mutations were identified in
		  one out of five (20%) patients with a family history and in one out of 14 (7%)
		  apparently sporadic cases. No <italic>BRCA1</italic> or <italic>BRCA2</italic> mutations were
		  found in female probands with nonfamilial bilateral breast cancer (10 cases)
		  and with breast cancer associated with gastrointestinal, pancreatic or uterine
		  cancers, synchronous/metachronous or in first-degree relative(s) (nine cases).
		  These cases were all diagnosed after age 40 years (Table <xref ref-type="table" rid="T5">5</xref>).</p></sec><sec><title>Discussion</title><p>We screened the coding sequences of the <italic>BRCA1</italic> and
		  <italic>BRCA2</italic> genes in 136 breast/ovarian cancer patients, including 102
		  females with breast cancer who were mostly at moderate risk for
		  mutation-carrier status, 15 females with breast-ovarian/ovarian cancer and 19
		  males with breast cancer. The sensitivity of the combined PTT/SSCP screening
		  assays is reportedly high [<xref ref-type="bibr" rid="B16">16</xref>]. The present results
		  should be regarded as an approximation, because the following types of mutation
		  are predicted to escape detection: mutations in noncoding regions, which are
		  estimated to account for a minimum of 10% of pathogenetic <italic>BRCA1</italic> and
		  <italic>BRCA2</italic> mutations [<xref ref-type="bibr" rid="B5">5</xref>]; missense mutations in
		  functionally important regions within <italic>BRCA1</italic> and <italic>BRCA2</italic> exons
		  11; large deletions undetectable by PCR-based assays; and mutations within the
		  first and last 180 nucleotides of the amplicons analyzed by PTT. In spite of
		  these limitations, the present study contributes evidence that is useful for
		  assessing the importance of <italic>BRCA1</italic> and <italic>BRCA2</italic> mutations in
		  patients who are not in high-risk families from outbred populations.</p><p>In contrast to studies on North and East European populations [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B27">27</xref>], the present results indicate a
		  lack of relevant founder effects for <italic>BRCA1-</italic> and <italic>BRCA2</italic>-related
		  disease in the sample of patients analyzed, which is in agreement with other
		  Italian studies [<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B29">29</xref>,<xref ref-type="bibr" rid="B30">30</xref>] and with ethnical and historical
		  data [<xref ref-type="bibr" rid="B15">15</xref>]. The <italic>BRCA1</italic> mutations detected in the
		  present study were previously reported in families with high cancer incidence
		  of different ethnic or geographic origin, but not in other Italian surveys
		  [<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B29">29</xref>,<xref ref-type="bibr" rid="B30">30</xref>]. Interestingly, three of the six
		  <italic>BRCA2</italic> mutations were nonsense and three were novel. <italic>BRCA2</italic>
		  6696delTC, reported in another series of Italian breast cancer patients [<xref ref-type="bibr" rid="B24">24</xref>] but only twice in the Breast Cancer Information Core
		  database, was the only mutation detected more than once. This mutation may
		  represent a candidate frequent mutation in the Italian population. A possible
		  common origin of the mutation detected in two unrelated patients could not be
		  verified, however, because the haplotypes of the mutation-bearing chromosomes
		  could not be reconstructed.</p><p>The contributions of <italic>BRCA1</italic> and <italic>BRCA2</italic> to breast/
		  ovarian cancer in Italian patients appear to be less significant than in
		  patients from communities with founder mutations [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B32">32</xref>]. The
		  present results are in agreement with recent direct estimates on other outbred
		  populations, which indicate that 7-10% of all female breast cancers that occur
		  before age 40 years are due to <italic>BRCA1</italic>/ <italic>BRCA2</italic> [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B32">32</xref>,<xref ref-type="bibr" rid="B33">33</xref>]. Moreover, the 8% <italic>BRCA1</italic> mutation rate found in
		  women with site-specific breast cancer diagnosed before age 40 years,
		  regardless of family history, is consistent with an indirect estimate that 5.3%
		  of all female breast cancers among those who are under 40 years old may be due
		  to mutations in <italic>BRCA1</italic> [<xref ref-type="bibr" rid="B34">34</xref>].</p><p>Overall, <italic>BRCA1</italic> and <italic>BRCA2</italic> equally contributed to
		  site-specific breast cancer in patients who reported one or two breast
		  cancer-affected first-/second-degree relative(s) or who were diagnosed before
		  age 40 years in the absence of a family history. This is consistent with recent
		  data [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B7">7</xref>] that indicated that the
		  respective frequencies of <italic>BRCA1</italic> and <italic>BRCA2</italic> mutations are
		  comparable in early onset breast cancer. Considering the total population of
		  patients analyzed here, however, <italic>BRCA1</italic> and <italic>BRCA2</italic> mutations
		  were mostly found in cases with disease diagnosis before and after age 50
		  years, respectively. Moreover, in cases with familial clustering of
		  site-specific breast cancer, <italic>BRCA1</italic> mostly accounted for tumours
		  diagnosed before age 40 years, and <italic>BRCA2</italic> for tumours diagnosed after
		  age 50 years. This is in agreement with a trend, observed in other populations,
		  for the proportion of cases with <italic>BRCA2</italic> mutations to increase, and the
		  proportion with mutations in <italic>BRCA1</italic> to decrease as the age at cancer
		  onset increases [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B31">31</xref>,<xref ref-type="bibr" rid="B35">35</xref>,<xref ref-type="bibr" rid="B36">36</xref>]. As in other studies [<xref ref-type="bibr" rid="B4">4</xref>], the frequency of <italic>BRCA1</italic>/<italic>BRCA2</italic> mutations
		  taken together was lower than the estimated frequencies at comparable ages for
		  all susceptibility alleles derived from the CASH study [<xref ref-type="bibr" rid="B3">3</xref>]. The discrepancy between direct data derived from
		  <italic>BRCA1IBRCA2</italic> mutational analysis and CASH estimates could be due to
		  several factors, including contribution(s) of gene(s) other than
		  <italic>BRCA1/BRCA2</italic>, differences between populations and relative
		  insensitivity of mutational screening.</p><p>In the present study, <italic>BRCA1</italic> mutations were detected in only
		  one out of 10 cases from breast/ovarian and site-specific ovarian cancer
		  families. This is a low proportion compared with studies that suggested that
		  <italic>BRCA1</italic> and <italic>BRCA2</italic> are responsible for the large majority of
		  breast/ovarian cancer families, with the greater proportion due to
		  <italic>BRCA1</italic> [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B31">31</xref>]. In this respect, the limits of
		  mutation detection techniques and the small number of breast/ovarian and
		  site-specific ovarian cancer cases tested should be taken into account,
		  together with the fact that most of the probands examined here were from
		  families with only one case of ovarian cancer.</p><p>As expected, <italic>BRCA2</italic> mutations were detected in male breast
		  cancer patients. <italic>BRCA2</italic> mutations were found in 20% of the males
		  reporting familial clustering of breast cancer. In the males with no family
		  history of breast/ovarian cancer, the proportion of carriers of <italic>BRCA2</italic>
		  mutations (7%) was comparable to that obtained for <italic>BRCA1</italic> and
		  <italic>BRCA2</italic> combined in site-specific female breast cancer patients (8%).
		  The overall proportion of cancer-affected males with <italic>BRCA2</italic> mutations
		  (10%) was high compared with data from other outbred populations, but was lower
		  than that reported for populations with founder effects [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B37">37</xref>].</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Oligonucleotide primers used for PTT and SSCP analyses</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Exon screened</td><td align="left">Primer</td></tr></thead><tbody><tr><td align="left">PTT</td><td></td></tr><tr><td align="left">&#x02003;<italic>BRCA1</italic> exon 11</td><td align="left">Br5'-S: 5'-GCTGCTTGTGAATTTTCTGAG-3'</td></tr><tr><td></td><td align="left">Br5'-A: 5'-GCCTGCAGTGATATTAACTGTCTG-3'</td></tr><tr><td></td><td align="left">Br3'-S: 5'-GAAGAAAGTGAACTTGATG-3'</td></tr><tr><td></td><td align="left">Br3'-A: 5'-TAAGTTTGAATCCATGCTTTG-3'</td></tr><tr><td align="left">&#x02003;<italic>BRCA2</italic> exon 10</td><td align="left">B10-S: 5'-TTTGGAAAAACATCAGGGAATT-3'</td></tr><tr><td></td><td align="left">B10-A: 5'-AAACACAGAAGGAATCGTCATC-3'</td></tr><tr><td align="left">&#x02003;<italic>BRCA2</italic> exon 11</td><td align="left">B11-1S: 5'-CATTCTTCTGTGAAAAGAAGCTG-3'</td></tr><tr><td></td><td align="left">B11-1A: 5'-TGGTTTGAATTAAAATCCTGC-3'</td></tr><tr><td></td><td align="left">B11-2S: 5'-TACATGAACAAATGGGCAGGAC-3'</td></tr><tr><td></td><td align="left">B11-2A: 5'-TCCAGTACCAACTGGGACAC-3'</td></tr><tr><td></td><td align="left">B11-3S: 5'-GATCAGAAACCAGAAGAATTGC-3'</td></tr><tr><td></td><td align="left">B11-3A: 5'-TTGGGATATTAAATGTTCTGGAGTA-3'</td></tr><tr><td></td><td align="left">B11-4S: 5'-TCACCTTGTGATGTTAGTTTG-3'</td></tr><tr><td></td><td align="left">B11-4A: 5'-GTTAGCATACCAAGTCTACTG-3'</td></tr><tr><td align="left">SSCP</td><td></td></tr><tr><td align="left">&#x02003;<italic>BRCA1</italic> exons 2, 3, 5-10, 12-24</td><td align="left">Reported by Friedman <italic>et al</italic> [<xref ref-type="bibr" rid="B17">17</xref>]</td></tr><tr><td align="left">&#x02003;<italic>BRCA2</italic> exons 2-9, 12, 13, 15, 16, 19-27</td><td align="left">Reported by Friedman <italic>et al</italic> [<xref ref-type="bibr" rid="B11">11</xref>]</td></tr><tr><td align="left">&#x02003;<italic>BRCA2</italic> exon 14</td><td align="left">B14-S: 5'-GTGTACTAGTCAATAAAC-3'</td></tr><tr><td></td><td align="left">B14-A: 5'-CATCACACAAATTGTCAT-3'</td></tr><tr><td align="left">&#x02003;<italic>BRCA2</italic> exon 18</td><td align="left">B18-S: 5'-GAATTCTAGAGTCACACTTCCT-3'</td></tr><tr><td></td><td align="left">B18-A: 5'-ACTGATTTTTACCAAGAGTGCA-3'</td></tr></tbody></table><table-wrap-foot><p>Sense primers used for PTT contain a T7 promoter and a eukaryotic
				translation initiation sequence: 5'
				-GGATCCTAATACGACTCACTATAGGGA-GACCACCATG-3'. A, antisense; S, sense.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Germline <italic>BRCA1</italic> and <italic>BRCA2</italic> mutations detected in
			 selected samples from 136 unrelated probands and clinicopathologic
			 correlations</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Sex</td><td align="center">Type of cancer</td><td align="center">Family history</td><td align="center">Gene</td><td align="center">Exon</td><td align="center">Codon</td><td align="center">Nucleotide</td><td align="center">Effect</td></tr></thead><tbody><tr><td align="left">Female</td><td align="center">Br (26)</td><td align="center">None</td><td align="center"><italic>BRCA1</italic></td><td align="center">11</td><td align="center">454</td><td align="center">1479</td><td align="center">delAG-ter454</td></tr><tr><td align="left">Female</td><td align="center">Ov (45)</td><td align="center">Mo: Ov (57)</td><td align="center"><italic>BRCA1</italic></td><td align="center">11</td><td align="center">502</td><td align="center">1623</td><td align="center">5bpdel-ter505</td></tr><tr><td align="left">Female</td><td align="center">Br (64)</td><td align="center">D: Br (24)</td><td align="center"><italic>BRCA1</italic></td><td align="center">11</td><td align="center">1254</td><td align="center">3880</td><td align="center">delAG-ter1265</td></tr><tr><td></td><td></td><td align="center">D: Br (41)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Female</td><td align="center">Br (38)</td><td align="center">Fa: Ga (64)</td><td align="center"><italic>BRCA1</italic></td><td align="center">5</td><td align="center">61</td><td align="center">300</td><td align="center">Cys/Gly</td></tr><tr><td></td><td></td><td align="center">Pa: Br (50)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Female</td><td align="center">bil Br (40)</td><td align="center">Mo: Br (49)</td><td align="center"><italic>BRCA1</italic></td><td align="center">16</td><td align="center">1655</td><td align="center">5083</td><td align="center">del19bp-ter1670</td></tr><tr><td align="left">Male</td><td align="center">Br (79)</td><td align="center">S: Br (35)</td><td align="center"><italic>BRCA2</italic></td><td align="center">11</td><td align="center">1293</td><td align="center">4109</td><td align="center">TTA-TAA</td></tr><tr><td></td><td></td><td align="center">S: Br (55)</td><td></td><td></td><td></td><td></td><td align="center">(Lys-Stop)</td></tr><tr><td></td><td></td><td align="center">S: Br (50)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td align="center">S: Col (47)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Female</td><td align="center">Br (55)</td><td align="center">S: Br (49)</td><td align="center"><italic>BRCA2</italic></td><td align="center">11</td><td align="center">1370</td><td align="center">4339</td><td align="center">CAG-TAG</td></tr><tr><td></td><td></td><td align="center">S: Pan (52)</td><td></td><td></td><td></td><td></td><td align="center">(Glu-Stop)</td></tr><tr><td></td><td></td><td align="center">B: Col (54)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Female</td><td align="center">Br (62)</td><td align="center">Mo: Br (59)</td><td align="center"><italic>BRCA2</italic></td><td align="center">11</td><td align="center">1629</td><td align="center">5117</td><td align="center">TCA-TGA</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td align="center">(Ser-Stop)</td></tr><tr><td align="left">Male</td><td align="center">Br (54)</td><td align="center">None</td><td align="center"><italic>BRCA2</italic></td><td align="center">11</td><td align="center">1906</td><td align="center">5950</td><td align="center">delCT-ter1909</td></tr><tr><td align="left">Female</td><td align="center">Br (57)</td><td align="center">S: Br (50)</td><td align="center"><italic>BRCA2</italic></td><td align="center">11</td><td align="center">2156</td><td align="center">6696</td><td align="center">delTC-ter2174</td></tr><tr><td align="left">2Female</td><td align="center">Br (34)</td><td align="center">None</td><td align="center"><italic>BRCA2</italic></td><td align="center">11</td><td align="center">2156</td><td align="center">6696</td><td align="center">delTC-ter2174</td></tr></tbody></table><table-wrap-foot><p>Numbers in parentheses indicate age at onset. B, brother; bil Br,
				bilateral breast cancer; Br, breast cancer; Col, colorectal cancer; D,
				daughter; Fa, father; Ga, gastric cancer; Mo, mother; Ov, ovarian cancer; Pa,
				paternal aunt; Pan, pancreatic cancer; S, sister.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T3"><label>Table 3</label><caption><p><italic>BRCA1</italic> and <italic>BRCA2</italic> mutations by sex, age at disease
			 diagnosis and presence of breast/ovarian cancer in first-/second-degree
			 relative(s) in the total population of 136 breast/ovarian cancer probands
			 analyzed</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"></td><td align="center" colspan="2">BRCA1</td><td align="center" colspan="2">BRCA2</td><td align="center" colspan="2">Total</td></tr><tr><td align="left"></td><td colspan="2"><hr></hr></td><td colspan="2"><hr></hr></td><td colspan="2"><hr></hr></td></tr><tr><td align="left">Characteristics of patients</td><td align="center">Positive (%)</td><td align="center">Negative</td><td align="center">Positive (%)</td><td align="center">Negative</td><td align="center">Positive (%)</td><td align="center">Negative</td></tr></thead><tbody><tr><td align="left">Age</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"> 50 years or under</td><td align="center">4 (6)</td><td align="center">64</td><td align="center">1 (1)</td><td align="center">67</td><td align="center">5 (7)</td><td align="center">63</td></tr><tr><td align="left"> Older than 50 years</td><td align="center">1 (1)</td><td align="center">67</td><td align="center">5 (7)</td><td align="center">63</td><td align="center">6 (9)</td><td align="center">62</td></tr><tr><td align="left">Sex</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"> Female</td><td align="center">5 (4)</td><td align="center">112</td><td align="center">4 (3)</td><td align="center">113</td><td align="center">9 (8)</td><td align="center">108</td></tr><tr><td align="left"> Male</td><td align="center">0 (0)</td><td align="center">19</td><td align="center">2 (10)</td><td align="center">17</td><td align="center">2 (10)</td><td align="center">17</td></tr><tr><td align="left">Cancer in relative(s)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"> Yes</td><td align="center">4 (6)</td><td align="center">66</td><td align="center">4 (6)</td><td align="center">66</td><td align="center">8 (11)</td><td align="center">62</td></tr><tr><td align="left"> No</td><td align="center">1 (1)</td><td align="center">65</td><td align="center">2 (3)</td><td align="center">64</td><td align="center">3 (4)</td><td align="center">63</td></tr></tbody></table><table-wrap-foot><p>Positive indicates the presence of deleterious mutations, whereas
				negative indicates the absence of such mutations.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Proportions of <italic>BRCA1</italic> and <italic>BRCA2</italic> mutations in 117
			 female breast/ovarian cancer probands, classified by number of cancer patients
			 in the family, age at disease diagnosis, site-specific breast or
			 breast-ovarian/ovarian cancer</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center" colspan="8">Age of proband at disease diagnosis</td></tr><tr><td></td><td colspan="8"><hr></hr></td></tr><tr><td align="left"></td><td align="center" colspan="2">40 years or less</td><td align="center" colspan="2">41-50 years</td><td align="center" colspan="2">51 years or more</td><td align="center" colspan="2">All ages</td><td></td></tr><tr><td align="left"></td><td align="center" colspan="2"><hr></hr></td><td align="center" colspan="2"><hr></hr></td><td align="center" colspan="2"><hr></hr></td><td align="center" colspan="2"><hr></hr></td><td></td></tr><tr><td align="left">Cancer patients</td><td align="center"><italic>BRCA1</italic></td><td align="center"><italic>BRCA2</italic></td><td align="center"><italic>BRCA1</italic></td><td align="center"><italic>BRCA2</italic></td><td align="center"><italic>BRCA1</italic></td><td align="center"><italic>BRCA2</italic></td><td align="center"><italic>BRCA1</italic></td><td align="center"><italic>BRCA2</italic></td></tr><tr><td align="left">in family<sup>&#x02020;</sup></td><td align="center">[% (<italic>n</italic>)]</td><td align="center">[% (<italic>n</italic>)]</td><td align="center">[% (<italic>n</italic>)]</td><td align="center">[% (<italic>n</italic>)]</td><td align="center">[% (<italic>n</italic>)]</td><td align="center">[% (<italic>n</italic>)]</td><td align="center">[% (<italic>n</italic>)]</td><td align="center">[% (<italic>n</italic>)]</td></tr></thead><tbody><tr><td align="left"><bold>Breast</bold></td></tr><tr><td align="left"> One</td><td align="center">4 (1/28)</td><td align="center">4 (1/28)</td><td align="center">0 (0/9)<sup>*</sup></td><td align="center">0 (0/9)<sup>*</sup></td><td align="center">0 (0/10)<sup>*</sup></td><td align="center">0 (0/10)<sup>*</sup></td><td align="center">2 (1/47)<sup>*</sup></td><td align="center">2 (1/47)<sup>*</sup></td></tr><tr><td align="left"> Two or three</td><td align="center">25 (2/8)</td><td align="center">0 (0/8)</td><td align="center">0 (0/13)</td><td align="center">0 (0/13)</td><td align="center">3 (1/34)</td><td align="center">9 (3/34)</td><td align="center">5 (3/55)</td><td align="center">5 (3/55)</td></tr><tr><td align="left"> Total</td><td align="center">8 (3/36)</td><td align="center">3 (1/36)</td><td align="center">0 (0/22)</td><td align="center">0 (0/22)</td><td align="center">2 (1/44)</td><td align="center">7 (3/44)</td><td align="center">4 (4/102)</td><td align="center">4 (4/102)</td></tr><tr><td align="left"><bold>Breast/ovary</bold></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"> None/one</td><td align="center">0 (0/1)</td><td align="center">0 (0/1)</td><td align="center">0 (0/1)</td><td align="center">0 (0/1)</td><td align="center">0 (0/3)</td><td align="center">0 (0/3)</td><td align="center">0 (0/5)</td><td align="center">0 (0/5)</td></tr><tr><td align="left"> None to two/</td><td align="center">-</td><td align="center">-</td><td align="center">25 (1/4)</td><td align="center">0 (0/4)</td><td align="center">0 (0/6)</td><td align="center">0 (0/6)</td><td align="center">10 (1/10)</td><td align="center">0 (0/10)</td></tr><tr><td align="left"> one or two</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"> Total</td><td align="center">0 (0/1)</td><td align="center">0 (0/1)</td><td align="center">20 (1/5)</td><td align="center">0 (0/5)</td><td align="center">0 (0/9)</td><td align="center">0 (0/9)</td><td align="center">7 (1/15)</td><td align="center">0 (0/15)</td></tr></tbody></table><table-wrap-foot><p><sup>&#x02020;</sup>Including proband; numbers of <italic>BRCA1</italic>-
				and <italic>BRCA2</italic>-positive cases over number of cases in each age subset are
				given in parentheses. <sup>*</sup>The 19 breast cancer patients with no
				familial clustering of breast/ovarian cancer diagnosed above age 40 years
				included 10 cases with bilateral breast cancer and nine patients with breast
				cancer associated with gastrointestinal, pancreatic or endometrial cancer
				(synchronous/metachronous, four cases; in a first-degree relative, five
				cases).</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T5"><label>Table 5</label><caption><p>Proportions of <italic>BRCA1</italic> and <italic>BRCA2</italic> mutations in 19 male
			 breast cancer probands classified by number of cancer patients in the family
			 and age at disease diagnosis</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center" colspan="6">Age of proband at disease diagnosis</td></tr><tr><td></td><td colspan="6"><hr></hr></td></tr><tr><td></td><td align="center" colspan="2">41-50 years</td><td align="center" colspan="2">51 years or more</td><td align="center" colspan="2">All ages</td></tr><tr><td><hr></hr></td><td colspan="2"><hr></hr></td><td colspan="2"><hr></hr></td><td colspan="2"><hr></hr></td></tr><tr><td align="left">Cancer patients</td><td align="center"><italic>BRCA1</italic></td><td align="center"><italic>BRCA2</italic></td><td align="center"><italic>BRCA1</italic></td><td align="center"><italic>BRCA2</italic></td><td align="center"><italic>BRCA1</italic></td><td align="center"><italic>BRCA2</italic></td></tr><tr><td align="left">in family<sup>*</sup></td><td align="center">[% (<italic>n</italic>)]</td><td align="center">[% (<italic>n</italic>)]</td><td align="center">[% (<italic>n</italic>)]</td><td align="center">[% (<italic>n</italic>)]</td><td align="center">[% (<italic>n</italic>)]</td><td align="center">[% (<italic>n</italic>)]</td></tr></thead><tbody><tr><td align="left">One</td><td align="center">0 (0/1)</td><td align="center">0 (0/1)</td><td align="center">0 (0/13)</td><td align="center">8 (1/13)</td><td align="center">0 (0/14)</td><td align="center">7 (1/14)</td></tr><tr><td align="left">Two or three</td><td align="center">0 (0/3)</td><td align="center">0 (0/3)</td><td align="center">0 (0/2)</td><td align="center">50 (1/2)</td><td align="center">0 (0/5)</td><td align="center">20 (1/5)</td></tr><tr><td align="left">Total</td><td align="center">0 (0/4)</td><td align="center">0 (0/4)</td><td align="center">0 (0/15)</td><td align="center">13 (2/15)</td><td align="center">0 (0/19)</td><td align="center">10 (2/19)</td></tr></tbody></table><table-wrap-foot><p><sup>*</sup>Including proband; numbers of <italic>BRCA1</italic>- and
				<italic>BRCA2</italic>-positive cases over number of cases in each age subset are given
				in brackets.</p></table-wrap-foot></table-wrap></sec></body><back><ack><sec><title>Acknowledgments</title><p>We acknowledge the assistance of Mr Paolo Mastranzo (Department of
			 Endocrinology and Oncology, University 'Federico II', Naples,
			 Italy). We are also grateful to the patients and their families. The study was
			 sponsored by the <italic>Associazione Italiana per la Ricerca sul Cancro</italic>
			 (AIRC), coordinated project 'Italian Consortium for Hereditary Breast
			 Cancer'. CDA is supported by an AIRC fellowship.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Claus</surname><given-names>EB</given-names></name><name><surname>Risch</surname><given-names>N</given-names></name><name><surname>Thompson</surname><given-names>WD</given-names></name></person-group><article-title>Genetic analysis of breast cancer in the Cancer and Steroid Hormone
			 Study.</article-title><source>Am J Hum Genet</source><year>1991</year><volume>48</volume><fpage>232</fpage><lpage>242</lpage><pub-id pub-id-type="pmid">1990835</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Szabo</surname><given-names>CI</given-names></name><name><surname>King</surname><given-names>M-C</given-names></name></person-group><article-title>Inherited breast and ovarian cancer. </article-title><source>Hum Mol Genet</source><year>1995</year><volume>4</volume><fpage>1811</fpage><lpage>1817</lpage><pub-id pub-id-type="pmid">8541881</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Claus</surname><given-names>EB</given-names></name><name><surname>Schildkraut</surname><given-names>JM</given-names></name><name><surname>Thompson</surname><given-names>WD</given-names></name><name><surname>Risch</surname><given-names>NJ</given-names></name></person-group><article-title>The genetic attributable risk of breast and ovarian cancer.</article-title><source>Cancer</source><year>1996</year><volume>77</volume><fpage>2318</fpage><lpage>2324</lpage><pub-id pub-id-type="pmid">8635102</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rahman</surname><given-names>N</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name></person-group><article-title>The genetics of breast cancer susceptibility.</article-title><source>Annu Rev Genet</source><year>1998</year><volume>32</volume><fpage>95</fpage><lpage>121</lpage><pub-id pub-id-type="pmid">9928476</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blackwood</surname><given-names>MA</given-names></name><name><surname>Weber</surname><given-names>BL</given-names></name></person-group><article-title><italic>BRCA1</italic> and <italic>BRCA2</italic>: from molecular genetics to
			 clinical medicine.</article-title><source>J Clin Oncol</source><year>1998</year><volume>16</volume><fpage>1969</fpage><lpage>1977</lpage><pub-id pub-id-type="pmid">9586917</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname><given-names>D</given-names></name><name><surname>Easton</surname><given-names>DF</given-names></name><name><surname>Stratton</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Genetic heterogeneity and penetrance analysis of the <italic>BRCA1</italic>
			 and <italic>BRCA2</italic> genes in breast cancer families. The Breast Cancer Linkage
			 Consortium.</article-title><source>Am J Hum Genet </source><year>1998</year><volume>62</volume><fpage>676</fpage><lpage>689</lpage><pub-id pub-id-type="pmid">9497246</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frank</surname><given-names>TS</given-names></name><name><surname>Manley</surname><given-names>SA</given-names></name><name><surname>Olopade</surname><given-names>OI</given-names></name><etal></etal></person-group><article-title>Sequence analysis of <italic>BRCA1</italic> and <italic>BRCA2</italic>: correlations
			 of mutations with family history and ovarian cancer risk. </article-title><source>J Clin Oncol</source><year>1998</year><volume>7</volume><fpage>2417</fpage><lpage>2425</lpage><pub-id pub-id-type="pmid">9667259</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Krainer</surname><given-names>M</given-names></name><name><surname>Silva-Arrieta</surname><given-names>S</given-names></name><name><surname>FitzGerald</surname><given-names>MG</given-names></name><etal></etal></person-group><article-title>Differential contributions of <italic>BRCA1</italic> and <italic>BRCA2</italic> to
			 early onset breast cancer.</article-title><source>N Engl J Med</source><year>1997</year><volume>336</volume><fpage>1416</fpage><lpage>1421</lpage><pub-id pub-id-type="pmid">9145678</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Phelan</surname><given-names>CM</given-names></name><name><surname>Lancaster</surname><given-names>LM</given-names></name><name><surname>Tonin</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Mutation analysis of the <italic>BRCA2</italic> gene in 49 site-specific
			 breast cancer families.</article-title><source>Nature Genet</source><year>1996</year><volume>13</volume><fpage>120</fpage><lpage>122</lpage><pub-id pub-id-type="pmid">8673090</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thorlacius</surname><given-names>S</given-names></name><name><surname>Olafsdottir</surname><given-names>G</given-names></name><name><surname>Tryggvadottir</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>A single <italic>BRCA2</italic> mutation in male and female breast cancer
			 families from Iceland with varied cancer phenotypes.</article-title><source>Nature Genet</source><year>1996</year><volume>13</volume><fpage>117</fpage><lpage>119</lpage><pub-id pub-id-type="pmid">8673089</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>LS</given-names></name><name><surname>Gayther</surname><given-names>SA</given-names></name><name><surname>Kurosaki</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Mutation analysis of<italic> BRCA1</italic> and <italic>BCRA2</italic> in a male
			 breast cancer population.</article-title><source>Am J Hum Genet</source><year>1997</year><volume>60</volume><fpage>313</fpage><lpage>319</lpage><pub-id pub-id-type="pmid">9012404</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mavraki</surname><given-names>E</given-names></name><name><surname>Gray</surname><given-names>IC</given-names></name><name><surname>Bishop</surname><given-names>DT</given-names></name><name><surname>Spurr</surname><given-names>NK</given-names></name></person-group><article-title>Germline <italic>BRCA2</italic> mutations in men with breast cancer. </article-title><source>Br J Cancer</source><year>1997</year><volume>76</volume><fpage>1428</fpage><lpage>1431</lpage><pub-id pub-id-type="pmid">9400938</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haraldsson</surname><given-names>K</given-names></name><name><surname>Loman</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>Q-X</given-names></name><etal></etal></person-group><article-title><italic>BRCA2</italic> germ-line mutations are frequent in male breast
			 cancer patients without a family history of the disease.</article-title><source>Cancer Res</source><year>1998</year><volume>58</volume><fpage>1367</fpage><lpage>1371</lpage><pub-id pub-id-type="pmid">9537231</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Csokay</surname><given-names>B</given-names></name><name><surname>Udvarhelyi</surname><given-names>N</given-names></name><name><surname>Sulyok</surname><given-names>Z</given-names></name><etal></etal></person-group><article-title>High frequency of germ-line <italic>BRCA2</italic> mutations among Hungarian
			 male breast cancer patients without family history.</article-title><source>Cancer Res</source><year>1999</year><volume>59</volume><fpage>995</fpage><lpage>998</lpage><pub-id pub-id-type="pmid">10070953</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Piazza</surname><given-names>A</given-names></name></person-group><article-title>A genetic history of Italy.</article-title><source>Ann Hum Genet </source><year>1988</year><volume>52</volume><fpage>203</fpage><lpage>213</lpage><pub-id pub-id-type="pmid">3074731</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Serova</surname><given-names>OM</given-names></name><name><surname>Mazoyer</surname><given-names>S</given-names></name><name><surname>Puget</surname><given-names>N</given-names></name><etal></etal></person-group><article-title>Mutations in <italic>BRCA1</italic> and <italic>BRCA2</italic> in breast cancer
			 families: are there more breast cancer-susceptibility genes?</article-title><source>Am J Hum Genet</source><year>1997</year><volume>60</volume><fpage>486</fpage><lpage>495</lpage><pub-id pub-id-type="pmid">9042907</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>LS</given-names></name><name><surname>Ostermyer</surname><given-names>EA</given-names></name><name><surname>Szabo</surname><given-names>CI</given-names></name><etal></etal></person-group><article-title>Confirmation of <italic>BRCA1</italic> by analysis of germline mutations
			 linked to breast and ovarian cancer in ten families. </article-title><source>Nature Genet</source><year>1994</year><volume>8</volume><fpage>399</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">7894493</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ottini</surname><given-names>L</given-names></name><name><surname>D'Amico</surname><given-names>C</given-names></name><name><surname>Noviello</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Novel deletion at codon 1254 of the <italic>BRCA1</italic> gene in an
			 Italian breast cancer kindred.</article-title><source>Hum Mutat</source><year>1998</year><volume>1(suppl)</volume><fpage>S237</fpage><lpage>S239</lpage><pub-id pub-id-type="pmid">9452097</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>H</given-names></name><name><surname>Behbakht</surname><given-names>K</given-names></name><name><surname>McGovern</surname><given-names>PE</given-names></name><etal></etal></person-group><article-title>Mutation analysis of the <italic>BRCA1</italic> gene in ovarian cancers.
			 </article-title><source>Cancer Res</source><year>1995</year><volume>55</volume><fpage>2998</fpage><lpage>3002</lpage><pub-id pub-id-type="pmid">7606717</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Couch</surname><given-names>FJ</given-names></name><name><surname>Weber</surname><given-names>BL and the Breast Information Core</given-names></name></person-group><article-title>Mutations and polymorphisms in the familial early-onset breast
			 cancer (<italic>BRCA1</italic>) gene.</article-title><source>Hum Mutat</source><year>1996</year><volume>8</volume><fpage>8</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">8807330</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hamann</surname><given-names>U</given-names></name><name><surname>Brauch</surname><given-names>H</given-names></name><name><surname>Garvin</surname><given-names>AM</given-names></name><name><surname>Bastert</surname><given-names>G</given-names></name><name><surname>Scott</surname><given-names>RJ</given-names></name></person-group><article-title>German family study on hereditary breast and/or ovarian cancer:
			 germline mutation analysis of the <italic>BRCA1</italic> gene.</article-title><source>Genes Chrom Cancer</source><year>1997</year><volume>18</volume><fpage>126</fpage><lpage>132</lpage><pub-id pub-id-type="pmid">9115962</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scholfield</surname><given-names>AC</given-names></name><name><surname>Haites</surname><given-names>NE</given-names></name></person-group><article-title>Novel 5bp germline deletion in exon 11 of the <italic>BRCA1</italic>
			 gene.</article-title><source>Hum Mutat</source><year>1998</year><volume>1(suppl)</volume><fpage>S187</fpage><lpage>S188</lpage><pub-id pub-id-type="pmid">9452081</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>H</given-names></name><name><surname>Chiu</surname><given-names>HC</given-names></name><name><surname>Bandera</surname><given-names>CA</given-names></name><etal></etal></person-group><article-title>Mutations of the <italic>BRCA2</italic> gene in ovarian carcinomas.</article-title><source>Cancer Res</source><year>1996</year><volume>56</volume><fpage>2738</fpage><lpage>2741</lpage><pub-id pub-id-type="pmid">8665505</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Benedetti</surname><given-names>VMG</given-names></name><name><surname>Radice</surname><given-names>P</given-names></name><name><surname>Pasini</surname><given-names>B</given-names></name><etal></etal></person-group><article-title>Characterization of ten novel and 13 recurring <italic>BRCA1</italic> and
			 <italic>BRCA2</italic> germline mutations in Italian breast and/or ovarian carcinoma
			 patients.</article-title><source>Hum Mutat</source><year>1998</year><ext-link ext-link-type="uri" xlink:href="http://www3.interscience.wiley.com"/><pub-id pub-id-type="pmid">10660329</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Petrij-Bosch</surname><given-names>A</given-names></name><name><surname>Peelen</surname><given-names>T</given-names></name><name><surname>van Vliet</surname><given-names>M</given-names></name><etal></etal></person-group><article-title><italic>BRCA1</italic> genomic deletions are major founder mutations in Dutch
			 breast cancer patients.</article-title><source>Nature Genet</source><year>1997</year><volume>17</volume><fpage>341</fpage><lpage>345</lpage><pub-id pub-id-type="pmid">9354803</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Claes</surname><given-names>K</given-names></name><name><surname>Machackova</surname><given-names>E</given-names></name><name><surname>De Vos</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Mutation analysis of the <italic>BRCA1</italic> and <italic>BRCA2</italic> genes
			 results in the identification of novel and recurrent mutations in 6/16 Flemish
			 families with breast and/or ovarian cancer but not in 12 sporadic patients with
			 early-onset disease.</article-title><source>Hum Mutat</source><year>1999</year><ext-link ext-link-type="uri" xlink:href="http://www3.interscience.wiley.com"/><pub-id pub-id-type="pmid">10090482</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Csokay</surname><given-names>B</given-names></name><name><surname>Tihomirova</surname><given-names>L</given-names></name><name><surname>Stengrevics</surname><given-names>A</given-names></name><name><surname>Sinicka</surname><given-names>O</given-names></name><name><surname>Olah</surname><given-names>E</given-names></name></person-group><article-title>Strong founder effects in <italic>BRCA1</italic> mutation carrier breast
			 cancer patients from Latvia.</article-title><source>Hum Mutat</source><year>1999</year><ext-link ext-link-type="uri" xlink:href="http://www3.interscience.wiley.com"/><pub-id pub-id-type="pmid">10447273</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Caligo</surname><given-names>MA</given-names></name><name><surname>Ghimenti</surname><given-names>C</given-names></name><name><surname>Cipollini</surname><given-names>G</given-names></name><etal></etal></person-group><article-title><italic>BRCA1</italic> germline mutational spectrum in Italian families from
			 Tuscany: a high frequency of novel mutations.</article-title><source>Oncogene</source><year>1996</year><volume>13</volume><fpage>1483</fpage><lpage>1488</lpage><pub-id pub-id-type="pmid">8875986</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Montagna</surname><given-names>M</given-names></name><name><surname>SantaCatterina</surname><given-names>M</given-names></name><name><surname>Corneo</surname><given-names>B</given-names></name><etal></etal></person-group><article-title>Identification of seven new <italic>BRCA1</italic> germline mutations in
			 Italian breast/ovarian cancer families. </article-title><source>Cancer Res</source><year>1996</year><volume>56</volume><fpage>5466</fpage><lpage>5469</lpage><pub-id pub-id-type="pmid">8968102</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Benedetti</surname><given-names>VMG</given-names></name><name><surname>Radice</surname><given-names>P</given-names></name><name><surname>Mondini</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Screening for mutations in exon 11 of the <italic>BRCA1</italic> gene in 70
			 Italian breast and ovarian cancer patients by protein truncation test. </article-title><source>Oncogene</source><year>1996</year><volume>13</volume><fpage>1353</fpage><lpage>1357</lpage><pub-id pub-id-type="pmid">8808710</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abeliovich</surname><given-names>D</given-names></name><name><surname>Kaduri</surname><given-names>L</given-names></name><name><surname>Lerer</surname><given-names>I</given-names></name><etal></etal></person-group><article-title>The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in
			 BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer
			 patients among Ashkenazi women.</article-title><source>Am J Hum Genet</source><year>1997</year><volume>60</volume><fpage>505</fpage><lpage>514</lpage><pub-id pub-id-type="pmid">9042909</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fitzgerald</surname><given-names>MG</given-names></name><name><surname>MacDonald</surname><given-names>DJ</given-names></name><name><surname>Krainer</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Germ-line BRCA1 mutations in Jewish and non-Jewish women with
			 early-onset breast cancer.</article-title><source>N Engl J Med</source><year>1996</year><volume>334</volume><fpage>143</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">8531968</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Langston</surname><given-names>AA</given-names></name><name><surname>Malone</surname><given-names>KE</given-names></name><name><surname>Thompson</surname><given-names>JD</given-names></name><etal></etal></person-group><article-title>BRCA1 mutations in a population-based sample of young women with
			 breast cancer. </article-title><source>N Engl J Med</source><year>1996</year><volume>334</volume><fpage>137</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">8531967</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname><given-names>D</given-names></name><name><surname>Easton</surname><given-names>DF</given-names></name><name><surname>Peto</surname><given-names>J</given-names></name></person-group><article-title>Estimates of the gene frequency of BRCA1 mutations and its
			 contribution to breast and ovarian cancer incidence. </article-title><source>Am J Hum Genet</source><year>1995</year><volume>57</volume><fpage>1457</fpage><lpage>1462</lpage><pub-id pub-id-type="pmid">8533776</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boyd</surname><given-names>J</given-names></name></person-group><article-title><italic>BRCA2</italic> as a low penetrance cancer gene. </article-title><source>J Natl Cancer Inst</source><year>1996</year><volume>88</volume><fpage>1408</fpage><lpage>1409</lpage><pub-id pub-id-type="pmid">8827021</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Narod</surname><given-names>SA</given-names></name></person-group><article-title>Hereditary breast carcinoma syndromes.</article-title><source>Cancer </source><year>1997</year><volume>80</volume><fpage>537</fpage><lpage>542</lpage></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Couch</surname><given-names>FJ</given-names></name><name><surname>Farid</surname><given-names>LM</given-names></name><name><surname>DeShano</surname><given-names>ML</given-names></name><etal></etal></person-group><article-title><italic>BRCA2</italic> germline mutations in male breast cancer cases and
			 breast cancer families.</article-title><source>Nature Genet</source><year>1996</year><volume>13</volume><fpage>123</fpage><lpage>125</lpage><pub-id pub-id-type="pmid">8673091</pub-id></citation></ref></ref-list></back></article>



